XLJU
KRKG
Market cap8.76bUSD
Oct 20, Last price
112.50EUR
Name
Krka dd Novo Mesto
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved in the research, production, promotion, and sale of various pharmaceutical goods. Its market presence spans Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and numerous other international territories. The company's offerings are categorized into prescription medications, over-the-counter products, and veterinary health solutions. Its prescription drug pipeline targets a broad spectrum of medical conditions, including cardiovascular disorders, gastrointestinal issues, central nervous system ailments, pain management, anti-infective treatments, conditions affecting blood and blood-forming organs, urological problems, diabetes, and oncology. The array of non-prescription items includes products for oral and throat care, cough and cold remedies, analgesics, nasal preparations, vitamin and mineral supplements, products designed to enhance cerebral and peripheral circulation, digestive aids, and various general healthcare products. Furthermore, Krka supplies animal health products such as anti-infectives, antiparasitics, and other specialized formulations for both livestock and companion animals. Beyond its pharmaceutical operations, the company also provides health resort and tourist services. Krka, d. d. was established in 1954 and has its corporate headquarters in Novo Mesto, Slovenia.
Related entities
Subsidiaries (2)
KRKA FARMACÊUTICA, SOCIEDADE UNIPESSOAL LDA
KRKA Finland Oy
Key people
Joze Mermal
Independent Chairman (President) of the Supervisory Board - Shareholders' Representative · since 2016
Joze Colaric
Chief Executive Officer, Chairman (President) of the Management Board · since 2005
Mateja Vrecer
Independent Vice Chairman (Deputy President) of Supervisory Board - Employees' Representative · since 2024
David Bratoz
Member of the Management Board · since 2015
Milena Kastelic
Member of the Management Board - Worker Director, Deputy Director of Pharmaceutical Production · since 2021
Ales Rotar
Member of the Management Board, Director of Pharmaceutical R&D and Production
Vinko Zupancic
Member of the Management Board, Director of API R&D, Production and Supply Chain · since 2010
Luka Cerar
Independent Member of the Supervisory Board - Shareholders' Representative · since 2023
Julijana Kristl
Independent Member of the Supervisory Board - Shareholders' Representative · since 2010
Independent Vice Chairman (Deputy President) of the Supervisory Board - Shareholders' Representative · since 2020
Mojca Osolnik Videmsek
Independent Member of the Supervisory Board - Shareholders' Representative · since 2019
Tomaz Sever
Independent Member of the Supervisory Board - Employees' Representative · since 2005
Mari Bozic
Independent Member of the Supervisory Board - Employees' Representative · since 2024
Boris Znidaric
Independent Member of the Supervisory Board - Shareholders' Representative · since 2016
Headquarters & legal address
Šmarješka cesta 006
Novo mesto 8501
SI
Novo mesto 8501
SI
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||